Farnesyltransferase Inhibitors Progeria
Oct. 4, 2024
Lonafarnib Pre-clinical Drug Supply Program | The Progeria Research Foundation A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model | PNAS Frontiers | Bacteria Are New Targets for Inhibitors of Human Farnesyltransferase Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome | Circulation | Farnesyltransferase Inhibitors Progeria